Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-25T18:05:25.165Z Has data issue: false hasContentIssue false
  • English
  • Français

Therapeutics for the Treatment of Insomnia

Published online by Cambridge University Press:  07 November 2014

Joseph A. Lieberman III
Joseph A. Lieberman III*
Affiliation:
Dr. Lieberman is professor of family medicine at Jefferson Medical College, Thomas Jefferson University, in Philadelphia, Pennsylvania, and speaker of the house of the Medical Society of Delaware in Newark, Delaware.
Get access Rights & Permissions [Opens in a new window]

Abstract

Insomnia is a disorder characterized by chronic sleep disturbance associated with daytime disability or distress, such as memory impairment and fatigue, that occurs despite adequate opportunity for sleep. Insomnia may present as difficulty falling/staying asleep or as sleep that is nonrestorative. Studies show a strong correlation between insomnia and impaired quality of life. Pain conditions and depression are commonly associated with insomnia, either as secondary or comorbid conditions. In addition, a greater incidence of anxiety, alcohol and drug dependence, and cardiovascular disease is found in people with insomnia. Data indicate insomnia results from over-engaged arousal systems. Insomnia patients experience increased metabolic rate, body temperature, and heart rate, and elevated levels of norepinephrine and catecholamines. Pharmacologic options for the treatment of insomnia include benzodiazepine hypnotics, a selective melatonin receptor agonist, and sedating antidepressants. However, insomnia may be best treated with cognitive-behavioral therapy and instruction in good sleep hygiene, either alone or in concert with pharmacologic agents. Studies on the effects of insomnia treatment use variable methodologies or do not publish negative results, and there are currently no studies of treatment focusing on morbidity. Further research is necessary to better understand the effects of insomnia therapies on medical and psychiatric disorders.

In this Clinical Information Supplement, Thomas Roth, PhD, describes the nature of insomnia and its pathophysiology. Next, Andrew D. Krystal, MD, MS, reviews morbidities associated with insomnia. Finally, Joseph A. Lieberman III, MD, MPH, provides an overview of therapeutics utilized in patients with insomnia, including behavioral therapies and pharmacologic options.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S10 , 2007 , pp. 9 - 12
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. 2005;22(2):1–30.Google Scholar
2.Bootzin, RR, Perlis, ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry. 1992;53(suppl):37–41.Google ScholarPubMed
3.HLBI Working Group on Insomnia. 1998. NIH Publication 98–4088.Google Scholar
4.Kupfer, DJ, Reynolds CF 3rd. Management of insomnia. N Engl J Med. 1997;336(5):341–346.CrossRefGoogle ScholarPubMed
5.Lippmann, S, Mazour, I, Shahab, H. Insomnia: therapeutic approach. South Med J. 2001;94(9):866–873.CrossRefGoogle ScholarPubMed
6.National Center on Sleep Disorders Research, National Heart, Lung, and Blood Institute, National Institutes of Health. Insomnia: assessment and management in primary care. Sleep. 1999;22(suppl 2):S402–S408.Google Scholar
7.Mendelson, WB, Caruso, C. Pharmacology in sleep medicine. In: Poceta, JS, Mitler, MM, eds. Sleep Disorders: Diagnosis and Treatment. Totowa, NJ: Humana Press; 1998:137–160.Google Scholar
8.Erman, MK. Insomnia. In: Poceta, JS, Mitler, MM, eds. Sleep Disorders: Diagnosis and Treatment. Totowa, NJ: Humana Press; 1998:21–51.Google Scholar
9.Jancin, B. Psychotropics modestly raise cardiac arrest risk. Clin Psych News. April, 2000:28.Google Scholar
10.National Institutes of Health Consensus Conference. Drugs and insomnia: the use of medications to promote sleep. JAMA. 1984;251:2410–2414.CrossRefGoogle Scholar
11.Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics Co; 1999.Google Scholar
12.Physicians' Desk Reference. 45th ed. Montvale, NJ: Medical Economics Co; 1991.Google Scholar
13. Lunesta [package insert]. Marlborough, MA; Sepracor, Inc.; 2005.Google Scholar
14. Ambien CR [package insert]. Bridgewater, NJ; sanofi-aventis; 2007.Google Scholar
15. Rozerem [package insert]. Deerfield, Il; Takeda Pharmaceuticals America; 2006.Google Scholar
16. Sonata [package insert]. Bristol, TN; King Pharmaceuticals; 2002.Google Scholar